Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Valeo Pharma Inc T.VPH

Alternate Symbol(s):  T.VPH.DB | VPHIF

Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler, Atectura Breezhaler and Allerject. The ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis and Ametop Gel 4%. The Company's wholly owned subsidiary is VPI Pharmaceuticals Inc.


TSX:VPH - Post by User

Comment by kooter33on Oct 14, 2021 5:55pm
165 Views
Post# 34007120

RE:Future thoughts

RE:Future thoughts
CanadianJrs wrote: Wondering what everyone's 5 year outlook is share price wise on this little lady. Has anyone asked management what their thoughts are on dividends in the future? That and if there's a planned up listing to the TSXV or TSX after we meet break even profitability or net positive?

5 year plan?  4 year plan 2025,,,,, 118M shares O/S FD, Revenues by 2024 projected to be $ 160M based on current product portfolio.  Generally you can expect between 6X to 9X sales ( from IR), therefore MC at 6X = $160M x 6/118M shares = $8.13/share.  MC @ 9X sales = $ 160M x 9/118M = $12.20/share.
Management expects to add new products to the portfolio thus the $160M revenue per year could be higher by 2025.  My thoughts they will reach the $ 160M by 2024.  So, nothing but upside from here. IMO.
uplisting to TSX by 2021 year end or Q1 of 2022.
<< Previous
Bullboard Posts
Next >>